Daratumumab

Generic Name
Daratumumab
Brand Names
Darzalex, Darzalex Faspro
Drug Type
Biotech
Chemical Formula
-
CAS Number
945721-28-8
Unique Ingredient Identifier
4Z63YK6E0E
Background

Daratumumab is an immunoglobulin G1 kappa monoclonal antibody developed by Janssen and Genmab. It was first described in the literature in 2010 as a monoclonal antibody that targets CD38+ multiple myeloma cells; the first of its kind.
...

Indication

Daratumumab is indicated as an intravenous injection alone or in combination with other medications for the treatment of multiple myeloma. It is available as a combination product with hyaluronidase for the treatment of adults with multiple myeloma as monotherapy or combination therapy and light chain amyloidosis in combination with other drugs.

Associated Conditions
Multiple Myeloma (MM), Primary Amyloidosis, Refractory Multiple Myeloma, Relapsed Multiple Myeloma
Associated Therapies
-
Clinical Trials
Related News

Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma

First Posted Date
2023-11-21
Last Posted Date
2024-01-03
Lead Sponsor
Wuhan Union Hospital, China
Target Recruit Count
54
Registration Number
NCT06140966
Locations
🇨🇳

Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China

IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers

First Posted Date
2023-11-07
Last Posted Date
2024-10-04
Lead Sponsor
Indapta Therapeutics, INC.
Target Recruit Count
128
Registration Number
NCT06119685
Locations
🇺🇸

Valkyrie Clinical Trials, Los Angeles, California, United States

🇺🇸

Stanford University, Stanford, California, United States

🇺🇸

Florida Cancer Specialists and Research Institute - Lake Mary Cancer Center, Lake Mary, Florida, United States

and more 10 locations

A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)

First Posted Date
2023-10-16
Last Posted Date
2024-07-30
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
53
Registration Number
NCT06083922
Locations
🇺🇸

Memorial Sloan Kettering Cancer Center Suffolk - Commack (Limited Protocol Activities), Commack, New York, United States

🇺🇸

Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison, New York, United States

🇺🇸

Memorial Sloan Kettering Nassau (Limited Protocol Activities), Uniondale, New York, United States

and more 7 locations

A Study Evaluating Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants With Relapsed or Refractory Multiple Myeloma

First Posted Date
2023-09-26
Last Posted Date
2024-12-02
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
316
Registration Number
NCT06055075
Locations
🇰🇷

Seoul St Mary's Hospital, Seoul, Korea, Republic of

🇦🇺

Princess Alexandra Hospital Woolloongabba; Clinical Hematology and Medical Oncology, Woolloongabba, Queensland, Australia

🇦🇺

Royal Adelaide Hospital, Adelaide, South Australia, Australia

and more 14 locations

MC210808 Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethasone (Ven-Dd), or Daratumumab-Lenalidomide-Dexamethasone (Ven-DRd) for the Treatment of Multiple Myeloma

First Posted Date
2023-09-18
Last Posted Date
2024-12-02
Lead Sponsor
Mayo Clinic
Target Recruit Count
100
Registration Number
NCT06042725
Locations
🇺🇸

Mayo Clinic in Rochester, Rochester, Minnesota, United States

Anti-CD38 Antibody With KRAS Vaccine and Anti-PD-1 Antibody in Subjects With Pancreatic Ductal Adenocarcinoma and Refractory Non-Small Cell Lung Cancer

First Posted Date
2023-08-29
Last Posted Date
2024-02-05
Lead Sponsor
Georgetown University
Target Recruit Count
54
Registration Number
NCT06015724
Locations
🇺🇸

Georgetown Lombardi Comprehensive Cancer Center, Washington, District of Columbia, United States

The Safety and Efficacy of CD38 Monoclonal Antibody Monotherapy for CaAMR in Renal Transplantation

Not Applicable
Recruiting
Conditions
Antibody-mediated Rejection
Kidney Tranplant
Interventions
Drug: Daratumumab
First Posted Date
2023-06-22
Last Posted Date
2023-09-14
Lead Sponsor
First Affiliated Hospital of Zhejiang University
Target Recruit Count
15
Registration Number
NCT05913596
Locations
🇨🇳

79# Qingchun Road, Hangzhou, Zhejiang, China

Daratumumab Maintenance Therapy for Improving Survival in Patients with Light Chain Amyloidosis, EMILIA Trial

First Posted Date
2023-06-12
Last Posted Date
2024-11-13
Lead Sponsor
Mayo Clinic
Target Recruit Count
96
Registration Number
NCT05898646
Locations
🇺🇸

Mayo Clinic in Arizona, Scottsdale, Arizona, United States

🇺🇸

Mayo Clinic in Rochester, Rochester, Minnesota, United States

Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma

First Posted Date
2023-06-09
Last Posted Date
2024-03-01
Lead Sponsor
Carl Ola Landgren, MD, PhD
Target Recruit Count
30
Registration Number
NCT05896228
Locations
🇺🇸

University of Miami, Miami, Florida, United States

Teclistamab-Daratumumab and Talquestamab-Daratumumab in Newly Diagnosed High-risk Multiple Myeloma

First Posted Date
2023-05-09
Last Posted Date
2023-11-29
Lead Sponsor
PETHEMA Foundation
Target Recruit Count
30
Registration Number
NCT05849610
Locations
🇪🇸

Hospital Doce de Octubre, Madrid, Spain

🇪🇸

Hospital Clinic i Provincial de Barcelona, Barcelona, Spain

🇪🇸

Hospital Virgen de la Arrixaca, Murcia, Spain

and more 7 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy